Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy

This publication has 46 references indexed in Scilit:

• Tipranavir
  Drugs, 2005
• GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy^*
  HIV Medicine, 2004
• Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy
  Mathematical Biosciences, 2004
• A Novel Antiviral Intervention Results in More Accurate Assessment of Human Immunodeficiency Virus Type 1 Replication Dynamics and T-Cell Decay In Vivo
  Journal of Virology, 2003
• Virtual Inhibitory Quotient Predicts Response to Ritonavir Boosting of Indinavir-Based Therapy in Human Immunodeficiency Virus-Infected Patients with Ongoing Viremia
  Antimicrobial Agents and Chemotherapy, 2002
• Amprenavir Inhibitory Quotient and Virological Response in Human Immunodeficiency Virus-Infected Patients on an Amprenavir-Containing Salvage Regimen without or with Ritonavir
  Antimicrobial Agents and Chemotherapy, 2002
• CD4⁺T Cell Kinetics and Activation in Human Immunodeficiency Virus–Infected Patients Who Remain Viremic Despite Long‐Term Treatment with Protease Inhibitor–Based Therapy
  The Journal of Infectious Diseases, 2002
• A stable latent reservoir for HIV-1 in resting CD4+ T lymphocytes in infected children
  Journal of Clinical Investigation, 2000
• Sustained CD4⁺T Cell Response after Virologic Failure of Protease Inhibitor–Based Regimens in Patients with Human Immunodeficiency Virus Infection
  The Journal of Infectious Diseases, 2000
• The Human Immunodeficiency Virus: Infectivity and Mechanisms of Pathogenesis
  Science, 1988